CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenue:
Total revenue	$ 52,465	$ 20,521	$ 94,019	$ 36,401
Cost of revenue:
Total cost of revenue	15,724	6,171	28,512	9,947
Gross profit	36,741	14,350	65,507	26,454
Operating expenses:
Research, development and clinical trials	8,291	6,714	14,162	14,248
Selling, general and administrative	29,356	17,381	54,340	31,320
Total operating expenses	37,647	24,095	68,502	45,568
Loss from operations	(906)	(9,745)	(2,995)	(19,114)
Other income (expense):
Interest expense	(2,505)	(972)	(3,596)	(1,932)
Other income (expense), net	2,431	(784)	2,986	(1,011)
Total other expense, net	(74)	(1,756)	(610)	(2,943)
Loss before income taxes	(980)	(11,501)	(3,605)	(22,057)
Provision for income taxes	(21)	(22)	(32)	(28)
Net loss	$ (1,001)	$ (11,523)	$ (3,637)	$ (22,085)
Net loss per share attributable to common stockholders, basic	$ (0.03)	$ (0.41)	$ (0.11)	$ (0.79)
Net loss per share attributable to common stockholders, diluted	$ (0.03)	$ (0.41)	$ (0.11)	$ (0.79)
Weighted average common shares outstanding, basic	32,545,352	27,983,629	32,403,597	27,967,072
Weighted average common shares outstanding, diluted	32,545,352	27,983,629	32,403,597	27,967,072
Net product revenue [Member]
Revenue:
Total revenue	$ 42,462	$ 17,922	$ 76,455	$ 32,861
Cost of revenue:
Total cost of revenue	8,558	4,080	15,864	7,458
Service Revenue [Member]
Revenue:
Total revenue	10,003	2,599	17,564	3,540
Cost of revenue:
Total cost of revenue	$ 7,166	$ 2,091	$ 12,648	$ 2,489